An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

TRILIPIX®

Drug Information Related Patent

Hold Company

ABBVIE

Learn More

Dosage and Administration

CAPSULE, DELAYED RELEASE;ORAL

Specification

EQ 45MG FENOFIBRIC ACID;EQ 135MG FENOFIBRIC ACID

Indication

TRILIPIX® is indicated for the treatment of severe hypertriglyceridemia and primary hypercholesterolemia or mixed dyslipidemia.

Use

Instructions for Use

API

CHOLINE FENOFIBRATE

API Structure

We Supply

CHOLINE FENOFIBRATE

Note:

In-house Standard
Facility GMP
DMF in processing

null

Note:

null

Note:

null

Drug Patent

Patent No	Expiration Date
7259186	2025/1/7

API Patent

Patent No	Expiration Date
7259186	2025/1/7

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION

Tel:
E-mail:
Address:
WhatsAPP

Member of

CERTIFICATION